Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that reimbursement is a major challenge for the growth of expensive biologic agents in the rheumatoid arthritis market. According to the new Spectrum report entitled Biologics Battle for Supremacy in the Rheumatoid Arthritis Marketplace, a rheumatoid arthritis patient faces bills between $9000-16,000 for a year's treatment with a biologic agent.
"High prices of biologic agents are driving the rheumatoid arthritis market growth, but these high prices also present significant reimbursement issues," said Melissa Garland, analyst at Decision Resources. "UCB/Celltech's emerging CDP-870 can be manufactured using a proprietary technology in E. coli at a cost much lower than that of other agents. This will give CDP-870 a price advantage."
About Spectrum from Decision Resources
Spectrum is a comprehensive executive advisory service that identifies and analyzes key business and technology drivers of the pharmaceutical and biotechnology markets.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/